237 related articles for article (PubMed ID: 10516698)
21. Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin's lymphoma.
Cervantes F; Shu XO; McGlave PB; Ramsay NK; Miller WJ; Kersey JH; Weisdorf DJ
Bone Marrow Transplant; 1995 Sep; 16(3):387-92. PubMed ID: 8535311
[TBL] [Abstract][Full Text] [Related]
22. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
Da WM; Zhong JT; Liu Y; Huang YS; Bai H; Wu XX; Ou YX; Wang CB; Xu SF
Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
[TBL] [Abstract][Full Text] [Related]
23. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients.
Colombat P; Donadio D; Fouillard L; Milpied N; Tilly H; Pico J; Abgrall JF; Coiffier B; Herbrecht R; Philip T
Bone Marrow Transplant; 1994 Feb; 13(2):157-62. PubMed ID: 8205084
[TBL] [Abstract][Full Text] [Related]
24. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
25. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
26. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
27. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
[TBL] [Abstract][Full Text] [Related]
28. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival.
González-Barca E; Fernández de Sevilla A; Domingo-Claros A; Romagosa V; Martín-Henao GA; De Sanjose S; Carmona M; Petit J; García J; Grañena A
Bone Marrow Transplant; 2000 Nov; 26(10):1051-6. PubMed ID: 11108302
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
30. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
31. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
Jost LM; Honegger HP; Stahel RA
Schweiz Med Wochenschr; 2000 Jan; 130(3):60-9. PubMed ID: 10683881
[TBL] [Abstract][Full Text] [Related]
32. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging.
Weisdorf DJ; Haake R; Miller WJ; McGlave PB; LeBien TW; Vallera DA; Lasky LC; Kim TH; Peterson BA; Ramsay NK
Bone Marrow Transplant; 1991 Aug; 8(2):135-42. PubMed ID: 1933055
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of moderate-grade and high-grade malignant lymphoma with autologous hematopoietic stem cell transplantation].
Wang AL; He ZD; Luo Y; Xiao LX; Liu XY; Zhu YH
Ai Zheng; 2003 Dec; 22(12):1317-20. PubMed ID: 14693059
[TBL] [Abstract][Full Text] [Related]
34. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
35. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Mendoza E; Territo M; Schiller G; Lill M; Kunkel L; Wolin M
Bone Marrow Transplant; 1995 Feb; 15(2):299-303. PubMed ID: 7773222
[TBL] [Abstract][Full Text] [Related]
37. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
[TBL] [Abstract][Full Text] [Related]
38. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
39. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Eide MB; Lauritzsen GF; Kvalheim G; Kolstad A; Fagerli UM; Maisenhölder M; Østenstad B; Fluge Ø; Delabie J; Aarset H; Liestøl K; Holte H
Br J Haematol; 2011 Mar; 152(5):600-10. PubMed ID: 21241276
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.
Friedberg JW; Kim H; Li S; Neuberg D; Boyd K; Daley H; Fisher DC; Gribben JG; Spitzer T; Freedman AS
Bone Marrow Transplant; 2003 Oct; 32(7):681-6. PubMed ID: 13130315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
